EP0449879A1 - Anticorps heterobifonctionnels se liant specifiquement a des plaquettes et a des agents thrombolytiques - Google Patents

Anticorps heterobifonctionnels se liant specifiquement a des plaquettes et a des agents thrombolytiques

Info

Publication number
EP0449879A1
EP0449879A1 EP19900900579 EP90900579A EP0449879A1 EP 0449879 A1 EP0449879 A1 EP 0449879A1 EP 19900900579 EP19900900579 EP 19900900579 EP 90900579 A EP90900579 A EP 90900579A EP 0449879 A1 EP0449879 A1 EP 0449879A1
Authority
EP
European Patent Office
Prior art keywords
antibody
heterobifunctional
antibodies
specificity
fab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19900900579
Other languages
German (de)
English (en)
Inventor
Chien-Hsing Chang
Peter E. Daddona
Donald S. Neblock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of EP0449879A1 publication Critical patent/EP0449879A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • HEF Heterobifunctional antibodies are antibodies or aggregates of
  • HBF antibodies which are specific for two different antigens.
  • HBF antibodies can comprise a single antibody or fragment having a bispecific antigen binding region (two different variable regions) or aggregates of two or more antibodies of different specificities.
  • Reading describes the production of antibodies having binding specificites for two desired antigens using a quadroma cell or a trio a cell. See U.S. Patent 4,474,893 (1984).
  • a quadroma cell is the fusion product of two different hybrido a cells each of which produce an antibody with a different specificity.
  • a trioma cell is the fusion product of a hybridoma and a lymphocyte which produces antibodies with two different binding specificities.
  • Segal et a_l. describe target specific cross- linked heteroantibodies which are used as cytotoxic agents in U.S. Patent 4,676,980 (1987). Staerz et al.
  • PNAS, j3_:1453-57 teach the use of a hybrid antibody that, can focus effector T cell activity and Milstein ⁇ t al. , (1983) Nature, 305;537-539 describe the use of hybrid antibodies in immunohistochemistry.
  • Platelet aggregation is an essential event in the formation of blood clots.
  • Blood clots serve to prevent the escape of blood cells from the vascular system under normal circumstances.
  • clots can restrict or totally occlude blood flow resulting in cellular necrosis.
  • Heart attack patients are typically treated with thrombolytic agents such as tissue plasminogen activator (tPA) or ⁇ treptokinase.
  • thrombolytic agents such as tissue plasminogen activator (tPA) or ⁇ treptokinase.
  • tPA tissue plasminogen activator
  • ⁇ treptokinase Thrombolytic agents dissolve the fibrin component of clots.
  • a major complication associated*with fibrinolysis is reoccl sion based on platelet aggregation which can result in further heart damage.
  • Glycoprotein (gp)IIb/IIIa receptors on the surface of platelets are known to be responsible for platelet aggregation.
  • Reagents which block these receptors such as receptor-specific antibodies are expected to reduce or prevent reocclusion following thrombolytic therapy and to accelerate the rate of thrombolysis.
  • An example is the urine monoclonal antibody 7E3 which inhibits platelet aggregation. See European Patent Application Nos. 205,207 and 206,532. Su marv of the Invention
  • This invention pertains to a heterobifunctional antibody (HBF antibody) having a first specificity for a platelet and a second specificity for a thrombolytic agent.
  • the HBF antibody is useful in thrombolytic therapy.
  • the HBF antibody binds to platelets and blocks platelet aggregation while simultaneously recruiting endogenous or pharmalogi- cally-administered thrombolytic agent and it may increase the efficiency of thro bolysis by specifically targeting a thrombolytic agent to a thrombus.
  • the HBF antibody of this invention is formed by combining antigen specificities from at least two parental antibodies, one parent having specificity for a platelet component, preferably a component involved in platelet aggregation such as platelet glycoprotein Ilb/IIIa receptor complex, and the other parent having non-neutralizing specificity for a thrombolytic agent such as tissue plasminogen activator (tPA) , streptokinase, or urokinase.
  • tPA tissue plasminogen activator
  • streptokinase streptokinase
  • urokinase urokinase
  • Figure 1 is a photograph of SDS-PAGE analysis of a 25G5x7E3 (anti-platelet x anti-tPA) HBF antibody.
  • the parental F(ab') 2 molecules were reduced, derivatized, and crosslinked, resulting in the appearance of a F(ab') 2 sized band which was not present in either of the reactant Fab' molecules.
  • Figure 2 is a photograph of the F(ab') 2 sized band on non-reducing SDS-PAGE after a two-stage purification process of a P4B6x7E3 (anti-platelet x anti-tPA) HBF antibody.
  • Figure 3 is a photograph which shows that a non-disulfide, covalent bond is present in the 25G5x7E3 (anti-platelet x anti-tPA) HBF antibody by the appearance of a Mr 50-60 kD band on SDS-PAGE in the presence of dithiothreitol. This band is absent in the fully reduced parental antibodies.
  • Figure 4 is a chromatogram of the analysis of a 25G5x7E3 (anti-platelet x anti-tPA) HBF antibody by gel filtration HPLC, showing the HBF antibody as a single major peak of approximately 115 kD when compared to molecular weight calibrators.
  • Figure 5 is a chromatogram of the 25G5x7E3 (anti-platelet x anti-tPA) HBF reaction mixture on HIC-HPLC which contains four major peaks.
  • the 25G5x7E3 (anti-platelet x anti-tPA) peak has a retention time of about 43 minutes which differs significantly from the parental F(ab') 2 molecules.
  • Figure 6 (a-c) are graphs showing the results of an immunoassay of a 25G5x7E3 (anti-platelet x anti tPA) HBF antibody detecting the immunoreactivity of both the anti-platelet and anti-tPA specificities.
  • the HBF antibodies of this invention have combined specificities for platelets and for a thrombolytic agent.
  • the preferred platelet speci ⁇ ficity of the HBF antibody is for the glycoprotein Ilb/IIIa receptor complex (GP Ilb/IIIa) .
  • the GPIIb/IIIa specificity is preferably provided by the monoclonal antibody 7E3. See Coller, B.S., J. Clin. Invest. 96:101 (1985) and European Patent Applications Nos. 205,207 and 206,532.
  • Antibodies for other platelet antigens can also be employed.
  • antibodies which are reactive with the platelet membrane protein GMP-140 such as the S12 antibody (McEver et al. , J. Biol. Chem.
  • Binding specificity for a thrombolytic agent is derived from an antibody specific for a thrombolytic agent.
  • the antibody should bind the thrombolytic agent at an epitope such that it does not neutralize or significantly abrogate its activity.
  • the pre- ferred binding specificity is for the thrombolytic agent human tPA, but antibodies with a binding specificity for other thrombolytic agents such as streptokinase and urokinase can also be used.
  • Takada et al. , Throm. Res., _42_:63 (1986) or platelet components (Coller et al. , J. Clin. Invest. , 76:101 (1985)) can be selected from those presently available or can be specially prepared.
  • the anti- bodies can be obtained using conventional monoclonal antibody methodology, e.g., the standard somatic cell hybridization techniques of Kohler and Mil- stein, Nature 256:495 (1975).
  • the preferred throm ⁇ bolytic agent specificity is provided by monoclonal antibodies 25G5 or P4B6, Holovet et al. ; Takada et al. , cited supra, both specific towards tPA.
  • HBF antibodies are produced by joining together variable regions of two or more parental antibodies using chemical, cell fusion, or genetic engineering techniques.
  • the parental antibodies are cleaved, preferably proteolytically, yielding F(ab-),, fragments of the parental antibodies.
  • the fragments are subsequently subjected to conditions under which the disulfide linkages in the hinge region are selectively reduced yielding Fab' molecules from each parental antibody.
  • One set of parental Fab 1 molecules is maintained in the free sulfhydryl form (Fab'-SH) while the second set of parental Fab' molecules is covalently modified with a chemical ⁇ rosslinker.
  • Any sulfhydryl-specific crosslinker capable of crosslinking Fab 1 molecules can be used.
  • the preferred crosslinking agents are those having two maleimide groups such as bis-maleimidomethyl ether (BMME) or o-phenylenedimaleimide. Procedures for crosslinking using these agents are known in the art. See Chang et al. , J. Nucl. Med.
  • the derivatized Fab' molecules from one parental antibody are mixed with the Fab'-SH molecules from the second parental antibody under conditions which allow c.ovalent coupling of the two molecules to occur.
  • the resulting product is a heterobifunctional F(ab') 2 molecule (HBF antibody) possessing both of the parental specificities.
  • the parental antibodies can be selected from any isotypic class of antibodies but it is preferred that the parental antibodies be matched isotypi- cally.
  • the parental antibodies used to produce the HBF antibody can be of chimeric human o ' rigin. Normally, however, they will be murine antibodies.
  • the HBF antibodies can be purified using any purification process capable of separating HBF antibodies from undesired antibodies or antibody fragments.
  • the preferred purification process is a two step purification process. In the first step, the lower molecular weight contaminants are removed using gel filtration chromatography. Examples of gels which are useful in this first step are dextran crosslinked with epichlorohydrin, allyl dextran crosslinked with N,N'- methylene bisacrylamide, or agarose. The preferred gel is allyl dextran crosslinked with N,N' -methylene bisacrylamide.
  • the second purification step is conducted using hydrophobic interaction chromatography (HIC) , preferably using high performance liquid chromatography (HPLC) , on a phenyl-derivatized packing.
  • HIC hydrophobic interaction chromatography
  • HPLC high performance liquid chromatography
  • gradient conditions are created using two buffer solutions which may vary depending on the given set of isotype-matched parental antibodies.
  • buffer solutions used as the decreasing gradient (Buffer A) are ammonium sulfate, ammonium acetate, and halide salts such as sodium or potassium chloride.
  • Buffer A ammonium sulfate, ammonium acetate, and halide salts such as sodium or potassium chloride.
  • the HIC is capable of separating molecules based on their hydrophobicity.
  • whole parental antibodies or antibody fragments can be linked together to produce a heteroaggregate, the HBF antibody.
  • a variety of crosslinking agents such as protein A, carbodiimide, and N-succinimidyl-3- (2-pyridyldithio) propionate (SPDP) , can be used to link the parental antibodies or antibody fragments. See Kranz et al. , Proc. Natl. Acad. Sci. USA, 7_8:5807 (1981); U.S. Patent 4,474,893.
  • the HBF antibodies can also be produced using cell fusion techniques as described in U.S. Patent 4,474,893, to Reading.
  • hybridoma cells which secrete the parental antibodies are fused together to form quadroma or trioma cells.
  • quadroma and trioma cells secrete bispecific antibodies possessing the antigen binding regions of both parental antibodies.
  • the HBF antibodies can also be produced using genetic engineering techniques. In these procedures, DNA encoding the heavy and light chain variable regions of each of the parental antibodies are introduced into an appropriate host cell, preferably a lymphoid cell (e.g., a myeloma cell) . The transformed cell synthesizes, assembles, and secretes the heterobifunctional immunoglobulin proteins. After the HBF antibodies are produced using any of the above techniques, the HBF antibodies are characterized and assayed for both immunoreac- tivities. A preferred assay is a solid phase im unoassay wherein a positive signal results only if both immunoreactivities (platelet specificity and thrombolytic specificity) are present.
  • a lymphoid cell e.g., a myeloma cell
  • the platelet component antigen is coated onto a solid phase and used as the capture antigen for the platelet specific HBF antibody.
  • Test solutions containing the synthetic HBF antibodies or appropriate controls are incubated in with the solid phase. Subsequently, the solid phase is incubated in the presence of a radiolabelled thrombolytic agent. Specific binding of the thrombolytic agent by HBF antibodies is thereby determined.
  • HBF antibodies of this invention can be tested.
  • a sample is prepared in such a way that induces aggregation.
  • Collagen can be introduced into a sample of whole blood to induce aggregation.
  • an HBF antibody can be added to the sample containing collagen induced aggregated platelets while a control sample can be prepared in the same manner omitting the HBF antibody.
  • the amount or degree of aggregation in both samples can be measured using an aggregometer (Helena Laboratories) .
  • the HBF antibodies of this invention can be used to block platelet aggregation while recruiting an endogenous or pharmalogically administered throm ⁇ bolytic agent to the site of a thrombus.
  • the HBF antibody may be administered simultaneously with or subsequent to administration of a thrombolytic agent.
  • the HBF antibody has thrombus inhibiting activity and it can also increase the efficiency of thro bolytic agents by attracting them to the thrombi.
  • the crosslinking technology used to create the heterobifunctional antibodies of this example is that of the first embodiment of chemically joining the antigen binding regions of the parental antibodies as taught by Chang et al. J. Nucl. Med. , 27, 1041, (1986) and Glennie et al. , J. Immunol. , 139, 2367, (1987).
  • IgGl murine monoclonal antibodies (one specific for human platelet receptor glycoprotein GPIIb/IIIa and the other specific for human tissue-type plasminogen activator) were cleaved with pepsin yielding F(ab')_ fragments which were subsequently subjected to cysteine reduction in order to reduce selectively only the hinge region disulfide linkages while leaving the heavy-light and i trachain bonds intact.
  • Reduction was accomplished by concentrating 10 mg of each parental F(ab') 2 to 20 rt ⁇ g/ml in 50 mM sodium borate, 100 mM NaCl (pH 8.0). 1M L-cysteine (free base) in 10 mM sodium phosphate, 150 mM NaCl (pH 7.2) was added to each of the F(ab') 2 to yield a final concentration of 20 mM cysteine. Reduction was allowed to proceed at 37°C for 1 hour. The resulting Fab 1 was derivatized with BMI-1E.
  • a 50 mM BMME stock was prepared in dimethylformamide, and the 7E3 Fab' solution was added over vortexing to enough 50 mM BMME to provide a 30:1 ratio of BMME to Fab 1 . This mixture was allowed to react at room temperature for 10 minutes and was then desalted as above. The desalted BMME-derivatized 7E3 Fab' was
  • a murine monoclonal IgGl designated 7E3 has been characterized (see Coller, B.S., J. Clin. Invest, 96, 101, (1985)) which recognizes a conformational determinant formed by the
  • IgGl antibodies have been tested for their ability to neutralize tPA activity in a standard chromogenic-substrate amidolysis assay in order to screen for antibodies which were non-neutralizing as candidates for the anti-tPA partner in the synthetic HBF antibody.
  • the chemical crosslinking reaction may result in several unwanted by-products as well as the desired HBF antibodies.
  • These by-products could be either one of the parental F(ab') 2 species reformed through BMME coupling or through oxidative reformation of hinge-region disulfides, unreacted parental Fab' molecules, or other unrelated by-products.
  • a two-stage purification method was developed which first resolves the lower molecular weight contaminants using gel filtration followed by high performance liquid chromatography (HPLC) using hydrophobic interaction chromatography (HIC) on a phenyl-derivatized packing.
  • HPLC high performance liquid chromatography
  • HIC hydrophobic interaction chromatography
  • the HIC is performed on a 7.5x75 mm column of Biorad TSK phenyi 5-PW equilibrated in 100 mM Na phosphate (pH 6.3) containing 1 M ( H 4 ) 2 SO.
  • Buffer A The gel filtration pool is separated in this system using a linear gradient of 0-100% of Buffer B at a flow of 1 ml/min. Buffer B contains 100 mM Na phosphate at pH 6.3. The linear gradient is run from 5 to 55 minutes after 5 minutes of isocratic elution in Buffer A. Buffer B is held at 100% from 55 to 70 minutes. The gradient conditions may vary for a given set of isotype-matched parental antibodies.
  • BMME-derivatized partner was 7E3 and the anti-tPA partner was reacted as the F(ab') fragment containing free sulfhydryls in the hinge region.
  • a HBF antibody could have been produced using the anti-tPA partners as the BMME-derivatized partner and the 7E3 fragment containing free sulfhydryls in the hinge region.
  • Figure 1 is a photograph showing the SDS-PAGE analysis of a typical sequence of processing of the parental F(ab') 2 molecules through reduction, derivatization, and crosslinking, resulting in the appearance of a F(ab') 2 sized band which was not present in either of the reactant molecules.
  • Figure 2 is a photograph showing the the F(ab') 2 sized band after the two-stage purification process on non-reducing SDS-PAGE.
  • Figure 3 demonstrates that a non-disulfide, covalent crosslink is present in the HBF by the appearance of a Mr 50-60 kD band in SDS-PAGE in the presence of dithiothreitol. This band is absent in either of the fully reduced parental antibodies.
  • Figure 4 shows the analysis of the 25G5x7E3 HBF antibody under native conditions by gel filtration HPLC which results in a single major peak with a Mr of approximately 115kD as determined by comparison to molecular weight calibrators.
  • the parental F(ab') 2 molecules used to create the HBF antibodies were determined to be baseline resolved in the HIC system. Thus, the presence of a peak with a retention time intermediate between the two parental F(ab') 2 molecules and which is characterized as predominantly F(ab') by SDS-PAGE is taken as evidence that a species comprised of half of each parental F(ab') 2 is present.
  • Figure 5 shows that the 25G5x7E3 (anti-platelet x anti tPA) HBF reaction mixture chromatogram on HIC-HPLC had 4 major peaks.
  • the HBF antibody was the third peak with a retention time of 43 minutes.
  • the F(ab') 2 or Fab' molecules chromatographed with retention times significantly different from the HBF peak.
  • the product HBF antibodies have been characterized in an immunoassay specifically designed to test for the presence of both parental immunoreactivities (platelet specificity and TPA specificity) . A positive signal results only if both immunoreactivities are present.
  • the platelet GPIIb/IIIa receptor is coated on flexible polyvinyl chloride 96-well plates and used as the capture antigen for the 7E3 partner of the HBF antibody.
  • Test solutions containing the synthetic HBF antibodies or appropriate controls parental F(ab') 2 species alone and in combination) are incubated in the wells and subsequently incubated in the presence
  • the HBF antibody (25G5 x 7E3) showed dose-dependent inhibition of human platelet aggregation similar to that observed for parental 7E3 F(ab') 2 or Fab' indicating that this parental function was retained by the HBF.
  • the slope of the line representative of aggregation is inversely proportional to the rate of platelet aggregation in this assay (i.e. as the slope of the line decreases, the effectiveness of the HBF antibody as a platelet aggregation inhibitor ' increases) .
  • a preliminary result demonstrated that the HBF (25G5 x 7E3) was more effective than 7E3 Fab' alone in preventing platelet aggregation when exogenous tPA was added to the whole blood.

Abstract

Des anticorps hétérobifonctionnels se lient à des plaquettes et à un agent thrombolytique. Ces anticorps hétérobifonctionnels sont utiles en thérapie thrombolytique.
EP19900900579 1988-11-25 1989-11-22 Anticorps heterobifonctionnels se liant specifiquement a des plaquettes et a des agents thrombolytiques Withdrawn EP0449879A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27628488A 1988-11-25 1988-11-25
US276284 1994-07-18

Publications (1)

Publication Number Publication Date
EP0449879A1 true EP0449879A1 (fr) 1991-10-09

Family

ID=23056015

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19900900579 Withdrawn EP0449879A1 (fr) 1988-11-25 1989-11-22 Anticorps heterobifonctionnels se liant specifiquement a des plaquettes et a des agents thrombolytiques

Country Status (2)

Country Link
EP (1) EP0449879A1 (fr)
WO (1) WO1990006133A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
JP2776634B2 (ja) * 1991-09-17 1998-07-16 帝人株式会社 グリコプロテイン ▲ＩＩ▼ｂ／▲ＩＩＩ▼ａに対するヒト型モノクローナル抗体
US6027725A (en) * 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
ZA937553B (en) * 1992-10-12 1994-05-03 Agen Ltd Clot directed anticoagulant process for making same and methods of use
AU5670194A (en) * 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
JPH0820586A (ja) 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
AU768295B2 (en) * 1998-11-03 2003-12-04 Centocor Inc. Modified antibodies and antibody fragments with increased duration of activity
CA2938363A1 (fr) 2014-02-07 2015-08-13 Katholieke Universiteit Leuven Ciblage double de tafi et pai-1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783330A (en) * 1984-11-15 1988-11-08 New England Medical Center Hospitals, Inc. Monoclonal antibodies to activated platelets
EP0241907A3 (fr) * 1986-04-14 1989-09-13 The General Hospital Corporation Anticorps hétérobifonctionnels et méthode d'utilisation
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
CA1339445C (fr) * 1986-11-12 1997-09-09 The General Hospital Corporation Molecules d'immunoglobuline hybride recombinante et methode d'utilisation
JPH03503840A (ja) * 1988-01-15 1991-08-29 セントコアー，インコーポレーテッド 異種連結抗体およびその治療的使用
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9006133A1 *

Also Published As

Publication number Publication date
WO1990006133A1 (fr) 1990-06-14

Similar Documents

Publication Publication Date Title
Dixit et al. A monoclonal antibody against human thrombospondin inhibits platelet aggregation.
EP0182634B1 (fr) Méthodes diagnostiques utilisant les anticorps
US4722903A (en) Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
CN110998329A (zh) 定性和/或定量分析可活化抗体的特性的方法及其用途
JP2002275196A (ja) レセプター誘発結合部位及びそれに対する抗体並びにその利用
JPH0646958B2 (ja) モノクローナル抗―ヒト乳癌抗体
KR940002033B1 (ko) 단백질 c에 대해 특이성이 있는 단클론성 항체 및 항체의 분리방법
EP0162078B1 (fr) Procede d'isolation d'une proteine d'un melange la contenant et un anticorps specifique de conformation
EP0449879A1 (fr) Anticorps heterobifonctionnels se liant specifiquement a des plaquettes et a des agents thrombolytiques
JPH05507268A (ja) 合成の抗体の誘導体の製造方法およびその中間体
JP2635343B2 (ja) ヘテロ二官能性抗体および利用方法
JPH06107700A (ja) Ｆ ＶＩＩＩ／ｖＷＦ複合体吸着のための免疫吸着材
Ploplis et al. Monoclonal antibodies to discrete regions of human Glu1-plasminogen
Branscomb et al. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator
Kimura et al. Monoclonal antibodies to human thrombomodulin whose binding is calcium dependent
US5534255A (en) Monoclonal antibody specific to human α2 -plasmin inhibitor
Charpie et al. A bispecific antibody enhances the fibrinolytic potency of single-chain urokinase
EP0206532A2 (fr) Anticorps monoclonal bloquant le fibrinogène
EP0271810A2 (fr) Détermination immunologique de la protéine S humaine libre et du complexe de la protéine S-c4bp
Boguslawski et al. Improved procedure for preparation of F (ab′) 2 fragments of mouse IgGs by papain digestion
JPH058679B2 (fr)
US5453269A (en) Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US5187067A (en) Immunological determination of free human protein S and C4bp-protein S complex
Soria et al. Immunochemical differentiation of fibrinogen fragment D or E and cross linked fibrin degradation products using monoclonal antibodies
IL91649A (en) A polydoma that produces, produces and uses two specific hybrid monoclonal antibodies against fibrin and pro-urokines

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910523

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19930506